Journal of Hematology & Thromboembolic Diseases
Open Access

Karel Forstier

Publications

• Research Article
  2014 WHO Clinical Molecular and Pathological (WHO-CMP) Diagnostic Criteria for the Classification and Staging of Five Distinct JAK2, MPL and CALR Mutated Myeloproliferative Neoplasms
  Author(s): Jan Jacques Michiels1*, Karel Forstier2, Fransje Valster3, Vincent Potters3, Katrien Schelfout3 and Hendrik De Raeve4,5Jan Jacques Michiels1*, Karel Forstier2, Fransje Valster3, Vincent Potters3, Katrien Schelfout3 and Hendrik De Raeve4,5
  
  Somatic mutations in the JAK2, MPL and calreticulin (CALR) genes are the driver causes of clonal myeloproliferative neoplasms (MPN). Applying the WHO Clinical, Molecular and Pathologic (WHO-CMP) classification of MPN, the JAK2V617F positive ET patients comprise three phenotypes of ET: normocellular ET, hypercellular ET due to increased erythropoiesis (prodromal PV) and ET with hypercellular megakaryocytic-granulocytic myeloproliferation (ET.MGM or masked PV). The percentage of JAK2V617F mutation load is low and stable in heterozygous normocellular ET and increasingly high in hetero/homozygous PV and masked PV. The JAK2V617F allele burden is related to MPN disease burden in terms of splenomegaly, constitutional symptoms and myelofibrosis. Five distinct clonal MPNs can be distinguished: JAK2V617F mutated ET and PV; JAK2 exon 12 PV and the JAK2 wild type ET and MF caused by the somatic m.. View More»
  DOI: 10.4172/2329-8790.1000172

  Abstract PDF

Relevant Topics